<DOC>
	<DOCNO>NCT02327416</DOCNO>
	<brief_summary>This study multi-center , randomize , prospective , open-label Phase III Clinical trial ass efficacy safety combination sequential treatment Y peginterferon Alfa-2b , entecavir GMCSF chronic hepatitis B patient nucleotides nucleoside experience . Patients randomize one 3 group receive different antiviral treatment .</brief_summary>
	<brief_title>A Prospective Clinical Trial Chronic Hepatitis B Patients NAs ( Nucleotides Nucleosides ) Experienced ( Anchor Study )</brief_title>
	<detailed_description>Patients pretreated respond one two nucleotide nucleoside least one year , HBV ( Hepatitis B Virus ) DNA less 1000 copies/ml HBsAg le 3000 IU/ml randomize one 3 group , receive Y peginterferon Alfa-2b 180mcg/week 96 week , entecavir 0.5 mg po daily 48 week plus GMCSF ( Granulocyte-macrophage colony stimulate factor ) 48 week , Y peginterferon Alfa-2b 180mcg/week 96 week entecavir 0.5 mg po daily 48 week , ETV 96 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Male female patient 18 65 year age ; 2 . HBsAg positive , entecavir adefovir dipivoxil use least 1 year include patient nucleotides nucleoside resistance history HBV DNA obtain control ; 3 . Before nucleotide nucleosides treatment , ALT &gt; 2 ULN , HBV DNA &gt; 10000 copies/ml , HBsAg positive ; 4 . Serum HBV DNA &lt; 1000 copies/ml ; 5 . Serum HBsAg &lt; 3000 IU/ml ; 6 . HBsAg positive ; 7 . Negative urine serum pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose test drug ; 8 . Absence cirrhosis confirm ultrasonic test ; 9 . Agree participate study sign patient inform consent . 1 . Patients NAs resistance HBV DNA &gt; 1000 copies/ml , treatment drug IFN longer 6 month ; 2 . Other antiviral , antineoplastic immunomodulatory treatment ( include supra physiologic dose steroid radiation ) 6 month prior first dose randomize treatment ( except 7 day acyclovir herpetic lesion 1 month prior first administration randomize treatment ) . Patients expect need systemic antiviral therapy provide study time participation also exclude ; 3 . Women ongoing pregnancy breastfeeding ; 4 . Coinfection active hepatitis A , hepatitis C , hepatitis D ( Those hospital ability test ) and/or human immunodeficiency virus ( HIV ) ; 5 . ALT &gt; 10 ULN ; 6 . Evidence decompensated liver disease ( ChildPugh score &gt; 5 ) . ChildPugh &gt; 5 mean , one follow 5 condition meet , patient exclude : one follow 5 condition meet , patient exclude : 1 . Serum albumin &lt; 3.5 g/L ; 2 . Prothrombin time &gt; 3 second prolong ; 3 . Serum bilirubin &gt; 34 Âµ mol/L ; 4 . History encephalopathy ; 5 . History variceal bleeding ; 6 . Ascites ; 7 . History evidence medical condition associate chronic liver disease viral hepatitis ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure , thalassemia ) ; 8 . Signs symptoms hepatocellular carcinoma , patient value alphafetoprotein &gt; 100 ng/mL exclude , unless stability ( le 10 % increase ) document least previous 3 month . Patients value &lt; 20 ng/mL &gt; 100 ng/mL may enrol , hepatic neoplasia exclude liver image ; 9 . Neutrophil count &lt; 1500 cells/mm3 platelet count &lt; 90,000 cells/mm3 screening ; 10 . Hemoglobin &lt; 11.5 g/dL female &lt; 12.5 g/dL men ; 11 . Serum creatinine level &gt; 1.5 ULN screening period . 12 . Phosphorus &lt; 0.65 mmol/L ; 13 . ANA &gt; 1:100 ; 14 . History severe psychiatric disease , especially depression . Severe psychiatric disease define treatment antidepressant medication major tranquilizer therapeutic dos major depression psychosis , respectively , least 3 month previous time history follow : suicidal attempt hospitalization psychiatric disease , period disability due psychiatric disease ; 15 . History severe seizure disorder current anticonvulsant use ; 16 . History immunologically mediate disease , ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , scleroderma , rheumatoid arthritis etc . ) ; 17 . History chronic pulmonary disease associate functional limitation ; 18 . Diseases IFN Nucleotides nucleoside suitable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>